Physician profile
Dan Tran
NPI 1487709747
$10,867.22
in general payments reported to CMS, 2019-2025
43 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 92% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $1,016 · 2021: $1,971 · 2022: $1,696 · 2023: $1,727 · 2024: $1,670 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,233.01 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,334.20 | 2019-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $1,332.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,150.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $959.52 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $565.25 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $367.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $257.02 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $240.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ironwood Pharmaceuticals, INC | $231.71 | 2021-2025 | Linzess |
| Gilead Sciences, INC. | $164.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $145.21 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $144.68 | 2019-2023 | Mitigare, Ryaltris |
| Merck Sharp & Dohme LLC | $139.56 | 2019-2025 | Verquvo, Gardasil, Gardasil 9 |
| Amarin Pharma, INC. | $136.45 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.